One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 diabetes ...

The FDA has designed five different types of labels, each presenting the same information but with different specifications based on the size of the packaging.

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

Patients on the once-weekly 7.2 milligram dose of Novo's drug for 72 weeks lowered their ... of Wegovy in adults with type 2 diabetes and obesity are expected within the next few months.

An international group of experts proposes two new categories of disease: preclinical and clinical obesity and the FDA ...